Earendil LabsIn Development
A half-life extended anti-TL1A monoclonal antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease, formulated at high protein concentration for subcutaneous injection.
Latest update Sep 18, 2026
01
Phase IIa ulcerative colitis, randomized and placebo-controlled, first patient dosed April 2, 2026. Australian Phase 1 healthy-volunteer study completed enrollment. Company-reported Phase 1: well tolerated at single doses up to 1,200 mg and multiple doses of 450 mg, about 8-week half-life, low anti-drug-antibody rate. No efficacy data disclosed. Crohn's studies have been discussed as a future use, not as an active trial.
02
03
Announced next steps from Earendil Labs that mention HXN-1001.
2027
Target2027 (no official window)
The randomized, placebo-controlled Phase IIa study that dosed its first patient on April 2, 2026 is the first test of whether HXN-1001 does anything in patients, not just healthy volunteers. No completion date, trial ID or primary-endpoint window has been disclosed. Watch for an efficacy and safety table, a Crohn's protocol, and whether the 8-week half-life holds in diseased patients.
04
Earendil's foundational protein-AI stack for antibody sequence design, structure and epitope prediction, biophysical-property scoring and closed-loop optimization, paired with high-throughput wet-lab validation. The public scientific ancestor is OmegaFold, Helixon's 2022 single-sequence structure predictor.
Two bispecific antibodies licensed exclusively to Sanofi for autoimmune and inflammatory bowel disease. HXN-1002 targets α4β7 and TL1A for moderate-to-severe ulcerative colitis and Crohn's disease. HXN-1003 targets TL1A and IL-23 and has shown synergistic activity in preclinical colitis and skin-inflammation models.
A recombinant humanized biparatopic antibody against two epitopes on TSLP that is designed to block both units of the heterodimeric TSLP receptor (TSLPR/CRLF2 and IL-7Rα). High-concentration subcutaneous formulation. Aimed at asthma, COPD and other TSLP-driven inflammatory diseases.
A preclinical oncology set listed on Earendil's pipeline page: CDH17 dual-payload ADC (HXN-2001), CEACAM5/CDH17 TCE and ADC, GUCY2C TCE, DLL3 TCE and dual-payload ADC, B7-H3 ADC, TROP2/PD-L1 and EGFR/PD-L1 bispecific ADCs, and a PD-1/IL-15 fusion protein. February 2026 WuXiTecan-2 license is meant to supply payload-linkers for a subset of these ADCs.
05
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.